Background
==========

Exhaled nitric oxide (FeNO) is associated with asthma \[[@B1]\], and with airway eosinophilia \[[@B2]\]. Recently, it was suggested that FeNO production in the airways is under the influence of Th2 cytokines, IL-4 and IL-13, responsible for induction of Inducible Nitric Oxide Synthase (iNOS) expression in the airway epithelium, and thus for the increase of FeNO in inflammatory disorders \[[@B3]\].

Many individual factors influence FeNO values. In fact, the considerable inter-subject variability hampers the clinical interpretation of FeNO measurements \[[@B4],[@B5]\]. Two important FeNO modifiers are atopy and rhinitis \[[@B6]\]. Some studies reported higher FeNO values in patients with atopy or allergic rhinitis alone \[[@B7]-[@B9]\], while others observed a relationship between elevated FeNO values and the exacerbation of rhinitis and the number of positive wheals on skin prick tests (SPT) \[[@B10],[@B11]\]. However, results are controversial, as there are studies that did not observe significant differences of FeNO values in atopy or rhinitis \[[@B12]-[@B14]\].

The aim of this systematic review was to evaluate the effect of atopy and rhinitis in FeNO values in otherwise healthy individuals.

Methods
=======

This systematic review follows the PRISMA recommendations \[[@B15]\]. Three databases were searched: Pubmed, Scopus and ISI Web of Knowledge. The limits used were a) English language, b) publication date from 1990 to October 2009, and c) studies with original data. The main search terms were \"FeNO\", \"Rhinitis, \"Atopy\" and equivalent expressions.

The inclusion criteria were: 1) atopy assessed by Skin Prick Tests (SPT) or specific IgE for common aeroallergens; 2) online FeNO measurements, according to the American Thoracic Society/European Respiratory Society (ATS/ERS) recommendations \[[@B6]\]; 3) study participants of at least two of the following groups: healthy, atopic, with allergic rhinitis or non allergic rhinitis. Exclusion criteria were 1) *in vitro*or animal experiments or 2) participants with known diseases other than rhinitis, e.g. asthma alone. A study group was defined as atopic in the presence of allergic sensitization without a medical diagnosis of asthma and rhinitis. Study selection had two phases (Figure [1](#F1){ref-type="fig"}). In Phase 1, two reviewers screened the titles and abstracts independently. If one of the reviewers included the abstract, it was allowed into the Phase 2. In Phase 2, manuscripts were analyzed independently and disagreements were discussed between reviewers

![**Articles selection process**.](2045-7022-1-8-1){#F1}

Data was extracted using an electronic form developed by the authors. Information on characteristics of the included studies and their samples was summarized in tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} and Additional File [1](#S1){ref-type="supplementary-material"} (tables S1-S2). Six studies did not present FeNO values. Authors were contacted for the FeNO data, but no answer was obtained. Four of these studies had FeNO values comparisons and were included, and the remaining 2 were excluded.

###### 

Description of the sample and methods of the studies included and how Atopy and Rhinitis were assessed

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Article                Setting                                                **Sample Size**^**‡**^   Age                               Sex (% of men)   Classification of:                  
  ---------------------- ------------------------------------------------------ ------------------------ --------------------------------- ---------------- ----------------------------------- ---------------------
  **Aronsson, 2005**     NI                                                     43^†^                    H: 41 (19-56);\                   11%              SPT                                 Symptoms
                                                                                                         AR: 33 (18-55)^§^                                                                      

                                                                                                                                                                                                

  **Berlyne, 2000**      Outpatient clinics                                     131^†^                   H: 36 (13);\                      43%              SPT                                 NA
                                                                                                         A: 37 (12)                                                                             

                                                                                                                                                                                                

  **Cardinale, 2005**    Outpatient clinics (healthy: schools)                  175^†^                   H: 10.3 (2.2);\                   29%              Specific IgE/Rast; Total IgE        Clinical Assessment
                                                                                                         AR: 10.1 (1.8)                                                                         

                                                                                                                                                                                                

  **Cibella, 2008**      NI                                                     335                      12.1 (10-16)^§^                   43%              SPT                                 Symptoms

                                                                                                                                                                                                

  **Gratziou, 2008**     Outpatient clinics (healthy: volunteers)               27^†^                    H: 36 (8);\                       37%              SPT                                 Symptoms
                                                                                                         AR: 35 (10)                                                                            

                                                                                                                                                                                                

  **Hervás, 2008**       Outpatient clinics                                     90                       10.8 (6-15)^§^                    64%              SPT                                 Clinical Assessment

                                                                                                                                                                                                

  **Hung, 2007**         Outpatient clinics                                     60                       5-14^\|\|^                        47%              Specific IgE                        Symptoms

                                                                                                                                                                                                

  **Kosticas, 2008**     Schools                                                219\*                    H: 21.4 (2.3); AR: 21.8 (3.0)     52%              SPT                                 Symptoms

                                                                                                                                                                                                

  **Malmberg, 2006**     Schools                                                276\*                    11.6 (6.9-15.7)^§^                51%              SPT                                 NA

                                                                                                                                                                                                

  **Manson, 2009**       NI                                                     20                       H: 23-48;\                        20%              SPT                                 Symptoms
                                                                                                         AR: 20-49^\|\|^                                                                        

                                                                                                                                                                                                

  **Marcucci, 2007**     NI                                                     41                       6 -10^\|\|^                       NI               SPT;\                               NA
                                                                                                                                                            Specific IgE/Rast                   

                                                                                                                                                                                                

  **Olin, 2004**         Workers                                                246^†^                   H: 44.5 (0.69); AR: 41.5 (1.51)   94%              Specific IgE/Rast                   Symptoms

                                                                                                                                                                                                

  **Prieto, 2002 (1)**   Outpatient clinics (Healthy: schools and volunteers)   48^†^                    H: 28.6 (9.2); AR: 33.0 (10.5)    54%              SPT                                 Clinical Assessment

                                                                                                                                                                                                

  **Prieto, 2002 (2)**   Outpatient clinics (Healthy: schools and volunteers)   24^†^                    H: 27.5 (3.3); AR: 34.9 (2.8)     33%              SPT                                 Clinical Assessment

                                                                                                                                                                                                

  **Profita, 2006**      NI                                                     91                       H: 10 (2.4);\                     59%              SPT; Specific IgE/Rast; Total IgE   Clinical Assessment
                                                                                                         AR: 9.9 (2.9)                                                                          

                                                                                                                                                                                                

  **Rolla, 2007**        Outpatient clinics                                     108^†^                   39.3 (11-75)^§^                   45%              SPT                                 Symptoms

                                                                                                                                                                                                

  **Rouhos, 2008**       General Population                                     248^†^                   45 (26-61)                        72%              SPT                                 NI

                                                                                                                                                                                                

  **Saito, 2004**        NI                                                     278                      10-12^\|\|^                       50%              Specific IgE/Rast                   NA

                                                                                                                                                                                                

  **Tanou, 2009**        NI                                                     70\*                     H: 31.8 (5.9); AR: 32.8 (7.2)     46%              SPT; Total IgE                      Symptoms
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NI - No Information; NA: Not Applicable; A: Atopic; AR: Allergic Rhinitis; H: Healthy

\* Sample includes smokers; ^†^Sample of non-smoker individuals; ^‡^See more information in Additional File [1](#S1){ref-type="supplementary-material"}. Age values are present as Mean (SD), otherwise indicated. ^§^Mean (Range); ^\|\|^Range.

###### 

Comparison of FeNO values between groups in the 18 studies included

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                    Studies in Children (n = 8)   Studies in Adults (n = 11)                                                                                                                                                                                                                                      
  ------------------------------------------------- ----------------------------- ---------------------------- ------- ------------- ------------ -------------- ---------------- -------- ---------------- ------------------------------- --------- --------------- ------------- ------------ -------- ------------- ---------------- -------- ----
  **FeNO Value**s                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                  

  **Atopic**                                        19 (1.21)                     \-                           14.6‡   33.3 (1.13)   \-           17.4\          FeNO values\     \-       \-               \-                              13.2^†^   \-              \-            11 (6)       .        16.5\         FeNO values\              
                                                                                                                                                  (5.5-95.2)\*   not present^§^                                                                                                                           (11.3-27.6)   not present^§^            

                                                                                                                                                                                                                                                                                                                                                  

  **AR**                                            26.3 (1.04)                   24.68 (19.2)                 \-      \-            15.3\        19.1\                                    25.1\            DS: 63.1(1.26) OS: 30.2(1.27)   24.5\     23.0\           17.0\         20.5\        \-       12.5\         31.0\                     
                                                                                                                                     (9.4-31.0)   (5.8-92.5)\*                             (5.7-102.9)^†^                                   (3.32)    (11.6-43.6)\*   (12.5-23.0)   (12.5-33)             (4.0-50.0)    (16.0-50.5)               

                                                                                                                                                                                                                                                                                                                                                  

  **NAR**                                           \-                            \-                           \-      \-            \-           12.6\                                    \-               \-                              16.1‡     \-              \-            \-           \-       \-            19.2\                     
                                                                                                                                                  (2.8-71.8)\*                                                                                                                                                          (14.1-22.0)               

                                                                                                                                                                                                                                                                                                                                                  

  **Healthy**                                       7.9 (0.96)                    9.44 (3.97)                  10.3‡   15.1 (1.14)   5.9\         13.1\                                    11.2\            12.6 (1.4)                      13.5\     15.5 †          10.5\         9.5\         9 (7)    3.8\          15.8\                     
                                                                                                                                     (3.4-9.3)    (3.0-71.0)\*                             (5.0-31.5)\                                      (0.9)                     (7.0-13.0)    (8.0-12.0)            (1.0-7.3)     (11.9-21.4)               
                                                                                                                                                                                           \*\*                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                  

  **Comparison of FeNO values between**^**\|\|**^                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                  

  **Atopic and Healthy**                            ↑↑                            \-                           ↑       ↑↑            \-           ↑              \-               \-       \-               \-                              \-        NS (↓)          \-            \-           NS (↑)   \-            NS (↑)           \-       \-

                                                                                                                                                                                                                                                                                                                                                  

  **AR and Healthy**                                ↑↑↑                           ↑↑↑                          \-      \-            ↑↑↑          NS (↑)         ↑                NS (↔)   ↑↑               E:↑↑↑\                          ↑↑        NR (↑)          ↑↑            ↑↑           \-       ↑↑↑           NR (↑↑)          NS (↔)   ↑
                                                                                                                                                                                                            NE:↑↑                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                  

  **NAR and Healthy**                               \-                            \-                           \-      \-            \-           NS (↓)         \-               \-       \-               \-                              NS (↑)    \-              \-            \-           \-       \-            NR (↑↑)          \-       \-

                                                                                                                                                                                                                                                                                                                                                  

  **AR and Atopic**                                 ↑                             \-                           \-      \-            \-           NS (↑)         \-               \-       \-               \-                              \-        NR (↑↑)         \-            \-           \-       \-            ↑↑               \-       \-

                                                                                                                                                                                                                                                                                                                                                  

  **AR and NAR**                                    \-                            \-                           \-      \-            \-           ↑              \-               \-       \-               \-                              ↑         \-              \-            \-           \-       \-            ↑                \-       \-

                                                                                                                                                                                                                                                                                                                                                  

  **Atopic and NAR**                                \-                            \-                           \-      \-            \-           NS (↑)         \-               \-       \-               \-                              \-        \-              \-            \-           \-       \-            NR (↓)           \-       \-
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are presented as Mean (SD) or as Median (Interquartil Range), otherwise indicated: \*Median (Range), †Mean (Range), ‡ Dispersion Measure not presented, ^§^The studies\' reports do not included numerical results. ^\|\|^Comparison was based in a ratio between FeNO values in each group: 1, 2 or 3 arrows means a ratio increase/decrease on FeNO values of 1,2 or 3 or more times, respectively. DS: During Season OS: Out of Season. Adult classification was defined as a mean/median age value ≥18 years. Atopic was defined as presence of allergic sensitization without asthma and without rhinitis. All comparisons are statistically significant (p \< 0.05), otherwise indicated. NR: Statistical significance not reported. NS: Not significant.

Two groups of studies were defined, based on the participants\' age - less than 18 years old and adults. In each group, the studies were divided according to the summary measure used for reporting FeNO values. Four groups of FeNO values were defined: Allergic Rhinitis (AR), Non-Allergic Rhinitis (NAR), Healthy and Atopic. Values were compared in sets of 2, with a total of 6 comparisons. A ratio of FeNO values in each comparison is presented. One study provided results during and off pollen season \[[@B16]\]. Both results were included, in separate conditions. When data allowed it, meta-analysis were done using Review Manager 5 (Cochrane Collaboration) \[[@B17]\] using a random effects model, due to differences on studies methods. Results showed high heterogeneity (I^2^) and were not included for analysis (Additional File [2](#S2){ref-type="supplementary-material"}, figures S1-S3).

Results
=======

Articles search retrieved a total of 2357 references after duplicates\' removal. In the first selection phase 2239 articles were excluded, mainly studies with patients with known conditions other than rhinitis (Figure [1](#F1){ref-type="fig"}). In the second selection phase, all full-text articles were retrieved and analyzed. Nineteen studies were included in the systematic review (Figure [1](#F1){ref-type="fig"}), in eight the participants were children and in 11 were adults. Most were cross sectional studies (n = 16), and 3 were prospective. Seven did not report the study setting, 8 recruited the subjects from outpatient clinics, 2 from schools, one from general population and another one from mills (Table [1](#T1){ref-type="table"}). Sample sizes ranged from 20 to 276 participants (Table [1](#T1){ref-type="table"}). Three studies included smokers and 9 included only non-smokers individuals; the remaining 7 studies did not report smoking status (Additional File [1](#S1){ref-type="supplementary-material"}, Table S1); one of the studies with children \[[@B11]\] excluded those that were exposed to tobacco smoke in the family.

Most studies used SPT to identify atopic patients (Table [1](#T1){ref-type="table"}). Rhinitis was defined based on symptoms (n = 9) or clinical assessment (n = 5) (Table [1](#T1){ref-type="table"}). The definition of healthy individuals was not reported in three studies, and all the others excluded atopic individuals (Additional File [1](#S1){ref-type="supplementary-material"}, Table S2).

Comparisons between defined groups were reported in all studies, but in 4 these comparisons did not present numerical values (Table [2](#T2){ref-type="table"}). Seven articles compared Atopic and Healthy individuals. The 3 studies performed in adults showed no significant differences in FeNO values, while in children, the studies showed higher FeNO values in the atopic groups. Sixteen articles compared FeNO values between Allergic Rhinitis and Healthy individuals in a total of 17 comparisons; 12 showed significant higher values of FeNO in the AR patients. Two studies compared Atopic and Non-Allergic Rhinitis individuals: one performed in children observed a non-significant higher in FeNO values in atopic individuals, while another, with an adult population, observed lower values. When comparing Allergic Rhinitis and Atopic individuals all the 4 studies (2 in children) showed higher FENO values in allergic rhinitis; in 2 of them the values were significantly higher and in the other the statistical significance was not reported. All articles comparing Allergic Rhinitis and Non-Allergic Rhinitis subjects (n = 3) showed higher FeNO values in allergic rhinitis patients. From the three articles comparing FeNO values between Non-Allergic Rhinitis individuals and Healthy ones, 2 had no significant differences, and one showed higher values in the NAR group (Figure [2](#F2){ref-type="fig"}).

![**Visualization of summaries of FeNO comparisons**. Groups with overlapping circles showed similar FeNO values. The radius of each circle is proportional to the number of articles measuring FeNO in each group. Upper limit of normal FeNO range was based on previous reports on children \[[@B21]\] and adults\' \[[@B20]\] FeNO values. Atopic was defined as presence of allergic sensitization without asthma and without rhinitis.](2045-7022-1-8-2){#F2}

The collected data was insufficient for quantitative synthesis. For each comparison, 2 to 3 studies could be used, and 2 out of the 3 meta-analysis had high heterogeneity (I^2^= 100%) (Additional File [2](#S2){ref-type="supplementary-material"}, Figures S1-S3).

Discussion
==========

This is the first systematic review that summarizes the influence of Allergic Rhinitis and Atopy on FeNO values. FeNO was higher in children with atopy and in children with allergic rhinitis, when compared with children without rhinitis, atopic or with NAR. In adults, a similar increase was observed with AR, but FeNO values were similar between atopic and healthy individuals. These results are in agreement with previous non-systematic reviews on AR effect on nasal and/or exhaled nitric oxide values \[[@B5],[@B18]\]. Previous results also support the consistent effect of atopy on FeNO values that we observed in healthy children; however they are not in agreement with the absence of effect of atopy in FeNO levels that we found in adults \[[@B5],[@B19]\]. Similar values were also observed between atopic individuals without rhinitis and patients with NAR and with NAR and healthy children. However, only 3 studies with patients with NAR were available.

This systematic review supports the argument that atopy and rhinitis should be considered for the clinical interpretation of FeNO measurements. In fact, adults with allergic rhinitis and children with atopy (those presenting higher FeNO levels) may have FeNO measurements out of the \'normal\' range previously proposed that do not take in account both atopy and rhinitis. To allow a visual representation of comparisons between groups we present the illustration in Figure [2](#F2){ref-type="fig"}\[[@B20],[@B21]\].

Our study has some limitations. The interpretation of quantitative synthesis of data was not possible. FeNO values were presented in different ways (e.g. different summary and dispersion measures) (Table [2](#T2){ref-type="table"}) so only 2 to 3 articles could be used for each comparison. Moreover, a high heterogeneity was observed (Additional File [2](#S2){ref-type="supplementary-material"}, Figure S1-S3). Despite our best efforts, we had no access to the values of FeNO in four studies. These articles were included on the review, allowing a broad qualitative assessment of published studies but could not be used in the meta-analysis.

The methods of the included studies were highly variable. There were variations in the definitions of atopy, rhinitis and healthy individuals. The definition of healthy individuals was particularly variable, often incomplete and sometimes missing. Also, various settings, eligibility criteria and sample sizes were used. In some of the studies with children \[[@B8],[@B12],[@B21]-[@B23]\] the age range was too broad (\> 5 years). FeNO in children is strongly associated with age and body size \[[@B5]\]. The inclusion criteria regarding smoking status were different and many did not report the smoking status (Additional File [1](#S1){ref-type="supplementary-material"}, Table S1). As smoking \[[@B9],[@B24]-[@B26]\], and passive smoking \[[@B27]\], can interfere with FeNO values, not accounting for the smoking status may be one of the reasons for the differences observed between the studies. Moreover, most studies presented only univariate analysis, with few multivariate models reported. Multivariate models could consider additional personal characteristics (e.g. height, age or gender).

Future studies should report adequate summary and dispersion measures, allowing for further quantitative synthesis. Samples sizes and subjects characteristics should be accurately described. Moreover, the factors that are known to modify FeNO should be taken into account. It is also important to follow current recommendations on FENO measurement \[[@B6]\].

In conclusion, FeNO values are higher in individuals with rhinitis and/or atopy without other diseases. These effects are small, seem to be independent and should be further studied using multivariate models. The causes for the effects of atopy and rhinitis on FENO values also need further study. The effect of atopy was observed only in children. The combined effect of atopy and rhinitis produced higher FeNO values in adults. These results support that atopy and rhinitis should be considered when interpreting or when defining FeNO reference values.
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